Response to Office Action dated April 8, 2009

Attorney Docket No.: 4544-060174

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

Claims 1-116 (canceled)

Claim 117 (currently amended): An effective and economical A method of processing a clinical samples sample useful for simple, rapid, safe, sensitive diagnosis of a bacterial infections infection such as tuberculosis and other mycobacterial infections caused by mycobacteria including M. tuberculosis and other infections caused by Gram-positive organisms like Staphylococcus sp. using a composition comprising Solution 1 comprising Universal Sample Processing (USP) solution comprising Guanidinium Hydrochloride (GuHC1) of concentration ranging between 3-6 M, Tris-Cl of concentration ranging between 40-60 mM of pH ranging between 7.3-7.7, EDTA of concentration ranging between 20-30 mM, Sarcosyl of concentration ranging between 0.3-0.8%, and beta-mercaptoethanol of concentration ranging between 0.1-0.3 M; Solution 2 selected from the group consisting of a) sodium phosphate of concentration ranging between 65 to 70 mM of pH ranging between 6.7 to 6.8; and b) sterile water; and one or more of Solution 3 comprising polysorbate 80 of concentration ranging between 0.03 to 0.08%, Solution A comprising a chelating resin suspension of concentration ranging between 8-12%, Solution B comprising polyoxyethylene phenyl ether of concentration ranging between 0.02 to 0.04%, or Solution C comprising polysorbate 20 of concentration ranging between 0.2-0.4% for isolating DNA, said method comprising steps of:

- (a) obtaining the clinical sample,
- (b) mixing 1.5 to 2 volumes of Solution 1 with the sample,
- (c) homogenizing the mixing-sample while avoiding frothing,
- (d) adding Solution 2 to the homogenate followed by centrifugation to obtain a pellet,
- (e) washing the pellet with Solution 1, optionally depending upon the decrease of the pellet size,
- (f) washing the Solution 1-washed pellet with water, and

Response to Office Action dated April 8, 2009

Attorney Docket No.: 4544-060174

(g) resuspending the water-washed pellet in one or more of Solution 3, Solution A, Solution B, and/or Solution C to obtain a processed sample for diagnosis, the processed sample being used in the form of smear, culture, or Polymerase chain reaction (PCR) starting material, using PCR amplifiable mycobacterial DNA, and RNA.

Claim 118 (currently amended): The method as claimed in claim 117, wherein homogenizing is conducted for a time duration of 20-120 seconds.

Claim 119 (previously presented): The method as claimed in claim 117, wherein the processing is completed in a total time duration ranging between 1-2 hours.

Claim 120 (previously presented): The method as claimed in claim 117, wherein Guanidinium Hydrochloride is present in a concentration of about 4 M and beta-mercaptoethanol in a concentration of about 0.1 M in the Universal Sample Processing (USP) solution for processing samples for culture and smear, said Guanidinium Hydrochloride being present in a concentration of about 5 M and said beta-mercaptoethanol in a concentration of between 0.1–0.2M for processing of samples for culture, smear and PCR, and said Guanidinium Hydrochloride being present in a concentration of 6 M and said beta-mercaptoethanol present in a concentration of about 0.2 M for samples processed for smear and PCR.

Claim 121-123 (canceled).

Claim 124 (previously presented): The method as claimed in claim 117, wherein PCR-amplifiable mycobacterial DNA and RNA can be obtained through simple-lysis by boiling in presence of Solution 3 or by adding 0.01-0.1% polyoxyethylene phenyl ether X 100.

Claim 125 (currently amended): The method as claimed in claim 117, wherein said <u>mixing</u>, homogenizing, adding, first washing, second washing, and resuspending steps are performed method in culture runs at a neutral pH.

Response to Office Action dated April 8, 2009

Attorney Docket No.: 4544-060174

Claim 126 (previously presented): The method as claimed in claim 117, wherein samples are stored at about -20°C for up to 2 months and can be processed for PCR, smear-microscopy and culture.

Claim 127 (currently amended): The method as claimed in claim 117 further comprising amplifying at least a fragment of a *devR* gene positioned between a first set of primers: , wherein said method in PCR uses two sets of primers namely, devRf2 and devRr2, or a second set of primers: devRf3[[,]] and devRr3—of gene *devR* of microbe *Mycobacterium tuberculosis*.

Claim 128 (currently amended): The method as claimed in claim 125, wherein the primers a devRf2 primer and a devRr2 primer amplify a 308 bp fragment of gene devR of microbe Mycobacterium tuberculosis, wherein the amplification of a 308 bp fragment indicates the presence of M. tuberculosis in the same.

Claim 129 (currently amended): The method as claimed in claim 125, wherein the primers a devRf3, primer and a devRr3 primer amplify a 164 bp fragment of gene the devR gene of microbe-Mycobacterium tuberculosis, wherein the amplification of a 164 bp fragment indicates the presence of M. tuberculosis in the same.

Claim 130 (withdrawn): A kit useful in processing clinical samples according to the method of claim 117, said kit comprising solution 1 consisting of Universal Sample Processing (USP) solution (composed of Guanidinium Hydrochloride (GuHC1) of concentration ranging between 3-6 M, Tris-C1 of concentration ranging between 40-60 mM of pH ranging between 7.3-7.7, EDTA of concentration ranging between 20-30 mM, Sarcosyl of concentration ranging between 0.3-0.8%, beta-mercaptoethanol of concentration ranging between 0.1-0.3 M), Solution 2 consisting of Sodium phosphate of concentration ranging between 65 to 70 mM of pH ranging between 6.7 to 6.8 (optionally can be replaced with water), Solution 3 consisting of Tween 80 of concentration ranging between 0.03 to 0.08%, Solution A comprising of Chelex 100 suspension of concentration ranging between 8-12%, Solution B consisting of Triton X-100 of concentration ranging between 0.02-0.04%, and Solution C consisting of Tween 20 of concentration ranging between 0.2 to 0.4, optionally

Response to Office Action dated April 8, 2009

Attorney Docket No.: 4544-060174

two sets of primers with devRf2 and devRr2 of SEQ ID No. 1 and SEQ ID No. 2 respectively, and primers devRf3, and devRr3 of SEQ ID No. 3, and SEQ ID No. 4 respectively.

Claim 131 (withdrawn): The kit as claimed in claim 130, wherein Guanidinium Hydrochloride is present in a concentration of about 4 M and beta-mercaptoethanol in a concentration of about 0.1 M in the Universal Sample Processing (USP) solution for processing sample cultures for smear, said Guanidinium Hydrochloride being present in a concentration of about 5 M and said beta-mercaptoethanol in a concentration of between 0.1–0.2 M for processing of samples for culture, smear and PCR, and said Guanidinium Hydrochloride being present in a concentration of 6 M and said beta-mercaptoethanol present in a concentration of about 0.2 M for samples processed for smear and PCR.

Claim 132 (withdrawn): The kit as claimed in claim 130, wherein the composition comprises solution 1 consisting of Universal Sample Processing (USP) solution, Solution 2 consisting of Sodium phosphate of concentration ranging between 65 to 70 mM of pH ranging 6.7 to 6.8, Solution 3 consisting Tween 80 of concentration ranging between 0.03 to 0.08%, Solution A comprising Chelex 100 suspension of concentration ranging between 8-12%, and Solution B consisting of Triton X-100 of concentration ranging between 0.02-0.04%, and Solution C consisting of Tween 20 of concentration ranging between 0.2-0.4%.

Claims 133-135 (canceled).